ANI Pharmaceuticals, Inc. ANIP R2KR3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.anipharmaceuticals.com

Company Profile ↓

$71.23

-19.73% 1Y

Mkt Cap$1.62B

P/E18.22

P/B2.97

52W High$98.81

52W Low$70.49

Book Value$26.34

EPS (TTM)$3.91

Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 18.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 66.6% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 54.8% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 18.2, below the sector median of 25.2.

Healthy Margins

Operating margin of 16.3% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $883.37M (+43.8% YoY); net profit $78.34M.
Trailing 12 Months Year-on-year growth — revenue +20.5%, earnings +86.1%.
5-Year Trend Long-term compounding — revenue CAGR 54.8%, profit CAGR 66.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	54.80%
1 Year:	20.50%

Compounded Profit Growth

5 Years:	66.65%
1 Year:	86.10%

Stock Price Performance

1 Year:	-19.73%
6 Months:	-3.80%
3 Months:	-12.18%
1 Month:	-13.80%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 3% of range

$70.49 $98.81

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
Death Cross7d ago
RSI (14)35.83 · Neutral

Price Performance

1M-13.80%

3M-12.18%

6M-3.80%

1Y-19.73%

Valuation vs Sector

P/E of 18.22 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 54.8% over 5 years.
Profit CAGR of 66.6% over 5 years.
Generates positive free cash flow.

CONS

Trading 27.9% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

18.22

Industry PE

25.17

Forward P/E

6.62

PEG Ratio

Book Value

$26.34

Price to Book

2.97

P/S

1.93

EV/EBITDA

10.42

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

54.80%

Profit 5Y

66.65%

Revenue (YoY)

20.50%

Earnings (YoY)

86.10%

Profitability & Returns

ROCE

6.99%

ROE

18.32%

ROA

4.97%

Profit Margin

9.98%

Op Margin

16.30%

Gross Margin

60.83%

EPS (Latest Qtr)

$1.05

EPS (TTM)

$3.91

Balance Sheet & Liquidity

Debt/Equity

1.12

Quick Ratio

2.43

Current Ratio

3.12

Debt

$630.21M

Total Assets

$1.49B

Current Assets

$747.08M

Working Capital

$475.00M

Ownership

Promoter Holding

5.43%

Chg in Prom Hold

-0.02%

FII / Inst Holding

107.30%

Chg in FII Hold

0.08%

Financial Snapshot

Enterprise Value

$1.62B

Total Revenue (TTM)

$923.71M

EBITDA

$197.38M

Free Cash Flow

$140.26M

Operating Cash Flow

$208.61M

Shares Outstanding

22.73M

Gross Margin

60.83%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	ANIP ANI Pharmaceuticals, Inc. R2KR3KPHARMA	71.23	18.22	$1.62B	0.00%	6.99%	18.32%	54.80%	66.65%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	36.63M	44.76M	48.16M	-	46.48M	47.27M	50.70M	-	52.89M	54.36M	51.34M	47.97M	49.77M	48.47M	52.98M	57.25M	54.52M	48.62M	52.06M	64.48M	73.86M	83.82M	106.79M	116.55M	131.83M	137.43M	138.04M	-	-	197.12M	211.37M	227.81M	247.06M	237.46M	266.04M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	73.04M	74.61M	93.39M	100.27M	93.58M	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124.08M	136.76M	134.42M	146.79M	143.88M	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109.98M	121.59M	111.59M	117.66M	105.17M	-
Operating Income	6.27M	5.67M	5.19M	7.92M	1.30M	4.62M	6.99M	9.33M	7.38M	6.54M	7.26M	10.11M	11.45M	4.40M	9.29M	7.33M	-4.67M	-7.84M	-11.31M	2.80M	331.00K	3.04M	-15.55M	-3.56M	-19.20M	-12.91M	-5.00M	9.89M	12.40M	17.95M	20.31M	5.17M	-	-	14.10M	15.17M	22.83M	29.13M	38.71M	40.46M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.36M	39.24M	61.16M	58.50M	64.91M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.48M	5.44M	4.73M	4.41M	3.77M	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.99M	10.53M	33.80M	31.48M	40.22M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.31M	1.98M	7.18M	3.99M	10.73M	-
Net Income	-	1.35M	1.12M	2.54M	-	1.15M	2.68M	4.72M	-	2.25M	2.78M	5.04M	-	449.00K	6.58M	3.90M	-4.83M	-7.01M	-12.34M	434.00K	-3.63M	86.00K	-14.11M	-4.45M	-20.13M	-14.92M	-8.60M	1.44M	6.25M	9.94M	18.21M	-2.29M	-	-	15.68M	8.55M	26.62M	27.49M	29.49M	24.71M
Diluted EPS	0.25	0.12	0.10	0.22	-0.09	0.10	0.23	0.40	-0.83	0.19	0.23	0.42	0.46	0.04	0.53	0.32	-0.41	-0.59	-1.03	0.04	-0.30	0.01	-1.17	-0.37	-1.27	-0.94	-0.55	0.06	0.29	0.45	0.82	-0.14	-	-	0.69	0.36	1.13	1.18	1.28	1.05
R&D Expense	-	966.00K	764.00K	1.04M	-	1.62M	2.17M	2.63M	-	2.10M	5.14M	4.67M	-	4.37M	5.77M	4.98M	-	6.34M	3.04M	2.94M	-	2.97M	2.81M	2.46M	5.27M	4.17M	7.66M	5.92M	7.37M	11.12M	10.51M	7.30M	10.13M	-	10.56M	16.54M	12.30M	-	10.60M	14.75M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.26M	2.47M	435.16K	20.37M	30.08M	55.97M	76.32M	128.62M	176.84M	201.58M	206.55M	208.47M	-	316.38M	486.82M	614.38M	883.37M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	138.78M	181.51M	250.21M	341.31M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	177.60M	305.30M	364.17M	542.06M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	203.33M	255.77M	361.95M	460.83M
Operating Income	-	-	-	-42.00K	898.00K	20.01M	32.70M	20.08M	28.33M	35.36M	16.35M	-16.02M	-	-25.73M	49.53M	2.22M	81.23M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	25.04M	106.60M	63.12M	207.27M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	28.05M	26.94M	17.60M	20.06M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-62.66M	19.87M	-22.21M	95.79M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-14.77M	1.09M	-3.69M	17.45M
Net Income	-47.53M	-46.20M	-51.61M	-1.51M	301.00K	28.75M	15.38M	3.93M	-1.08M	15.49M	6.09M	-22.55M	-	-47.90M	18.78M	-18.52M	78.34M
Diluted EPS	-1.40	-4.21	-3.15	-1.27	-0.92	2.59	1.32	0.34	-0.09	1.30	0.50	-1.88	-	-3.05	0.85	-1.04	3.32
R&D Expense	13.68M	39.71M	44.18M	1.16M	1.71M	2.68M	2.87M	2.91M	9.07M	15.39M	19.81M	16.00M	11.37M	22.32M	34.29M	44.58M	51.66M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	44.77M	62.38M	13.75M	44.50M	259.56M	285.26M	322.86M	412.14M	430.60M	456.79M	461.19M	-	760.09M	904.42M	1.28B	1.44B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	344.26M	519.82M	528.46M	753.12M
Cash & Equivalents	11.76M	29.86M	38.16M	0	11.00K	11.11M	169.04M	154.68M	27.36M	31.14M	43.01M	62.33M	7.86M	-	48.23M	221.12M	144.86M	285.58M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105.36M	111.20M	136.78M	143.07M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	165.44M	162.08M	221.73M	281.08M
Total Liabilities	-	-	25.62M	24.56M	10.59M	3.54M	119.77M	125.18M	153.22M	237.38M	233.34M	244.00M	265.49M	-	421.55M	446.82M	855.94M	899.65M
Current Liabilities	-	-	8.18M	7.23M	7.71M	3.54M	13.23M	11.76M	31.95M	39.23M	165.55M	61.68M	78.56M	-	99.44M	145.48M	194.45M	278.11M
Long Term Debt	-	-	-	-	-	-	106.54M	113.43M	0	69.95M	67.30M	175.81M	172.44M	-	285.67M	284.82M	614.92M	599.77M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	286.52M	285.67M	624.09M	617.03M
Total Equity	13.83M	15.83M	19.15M	-34.28M	-42.72M	40.96M	139.78M	160.08M	169.65M	174.76M	197.26M	212.79M	195.70M	-	338.54M	457.60M	428.53M	540.72M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.64M	20.73M	21.54M	23.11M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-137.00K	-5.48M	22.03M	17.26M	27.47M	39.42M	67.07M	45.63M	15.27M	-	-31.20M	118.96M	64.02M	185.22M
Investing Cash Flow	-	-	-	-	-	-35.75M	-32.68M	-149.06M	-107.99M	-27.38M	-27.55M	-68.32M	-	-15.74M	-18.51M	-404.72M	-34.32M
Financing Cash Flow	-	-	-	440.00K	-3.69M	171.65M	1.07M	-729.00K	72.36M	-27.82M	1.25M	-1.44M	-	-5.13M	67.44M	264.94M	-9.94M
Capital Expenditure	-165.72K	-63.44K	-719.92K	-292.00K	-191.00K	-1.12M	-2.18M	-4.57M	-10.37M	-5.74M	-6.63M	-6.13M	-	-16.45M	-18.51M	-16.95M	-34.32M
Free Cash Flow	-	-	-	-429.00K	-5.67M	20.91M	15.08M	22.91M	29.05M	61.33M	39.00M	9.13M	-	-47.66M	100.45M	47.06M	150.90M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-52.07M	167.89M	-75.76M	140.96M
Share Buybacks	-	-	-	0	433.00K	0	0	2.50M	0	0	1.03M	1.52M	890.00K	1.96M	4.99M	10.96M	12.21M
Dividends Paid	-	-	-	-	-	-	-	-	-	-	0	0	190.00K	1.62M	1.62M	1.62M	1.16M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	56.1%	62.7%	59.3%	61.4%
Operating Margin %	-	-	-	-0.2%	3.0%	35.7%	42.8%	15.6%	16.0%	17.5%	7.9%	-7.7%	-	-8.1%	10.2%	0.4%	9.2%
Net Margin %	-3,777.9%	-1,867.1%	-11,859.7%	-7.4%	1.0%	51.4%	20.1%	3.1%	-0.6%	7.7%	3.0%	-10.8%	-	-15.1%	3.9%	-3.0%	8.9%
ROE %	-300.2%	-241.3%	150.5%	3.5%	0.7%	20.6%	9.6%	2.3%	-0.6%	7.9%	2.9%	-11.5%	-	-14.1%	4.1%	-4.3%	14.5%
ROCE %	-	-	-	-0.7%	2.2%	8.1%	12.0%	6.9%	7.6%	13.3%	4.1%	-4.2%	-	-3.9%	6.5%	0.2%	7.0%

Shareholding Pattern

Insiders

5.43%

Institutions

107.30%

Public Float

113.45%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	12.89%	2.96M	$215.48M
2	Soleus Capital Management, L.P.	3.78%	867.76K	$63.20M
3	Vanguard Capital Management LLC	3.65%	838.22K	$61.05M
4	State Street Corporation	3.62%	831.65K	$60.57M
5	Tang Capital Management, LLC	3.08%	707.50K	$51.53M
6	Dimensional Fund Advisors LP	2.72%	623.46K	$45.41M
7	American Century Companies Inc	2.50%	574.47K	$41.84M
8	Arrowstreet Capital, Limited Partnership	2.45%	562.02K	$40.93M
9	Global Alpha Capital Management Ltd.	2.43%	558.00K	$40.64M
10	Geode Capital Management, LLC	2.34%	536.41K	$39.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ANIP

Yahoo Finance Fri, 04 Sep 2026

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthus…

Yahoo Finance hu, 27 Aug 2026

2 Reasons to Like ANIP (and 1 Not So Much)

ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500’s 11.7% gain during that period.…

Yahoo Finance Mon, 24 Aug 2026

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addi…

Yahoo Finance Sun, 16 Aug 2026

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cor…

Yahoo Finance Fri, 14 Aug 2026

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

Yahoo Finance Fri, 14 Aug 2026

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

Rare disease revenue surged 43.5% as Cortrophin Gel sales accelerated across key specialties.

ANIP — Frequently Asked Questions

What is the current share price of ANI Pharmaceuticals, Inc. (ANIP)?

As of 2026-09-07 16:24 PDT, ANI Pharmaceuticals, Inc. (ANIP) trades at $71.23 on NasdaqGM. Its 52-week range is $70.49 to $98.81.

What is the market capitalisation of ANIP?

ANI Pharmaceuticals, Inc. (ANIP) has a market capitalisation of $1.62B on NasdaqGM.

What is the P/E ratio of ANIP?

ANIP trades at a trailing price-to-earnings (P/E) ratio of 18.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.97.

What is the return on equity (ROE) of ANIP?

ANIP has a return on equity (ROE) of 18.32%. Its return on capital employed (ROCE) is 6.99%.

Is ANIP a good stock to buy?

This page provides a data-driven analysis of ANI Pharmaceuticals, Inc. (ANIP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

ANI Pharmaceuticals, Inc. ANIP R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board

2 Reasons to Like ANIP (and 1 Not So Much)

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?

ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript

ANIP — Frequently Asked Questions

What is the current share price of ANI Pharmaceuticals, Inc. (ANIP)?

What is the market capitalisation of ANIP?

What is the P/E ratio of ANIP?

What is the return on equity (ROE) of ANIP?

Is ANIP a good stock to buy?

Explore More